HORSHAM, PA, USA—AUGUST 16, 2011—Breakout sessions for study design and analysis as well as expert panel discussions will highlight DIA’s Optimizing Dosing for the Safe and Effective Use of Drugs in Patients with Renal Impairment Conference, which will be held September 19-20 in Washington, DC.
Patients with renal impairment are at increased risk for developing drug-related adverse events, says In these patients drug dosage needs to be closely monitored and adjusted to reflect altered pharmacokinetics (PK) and pharmacodynamics (PD) parameters. This conference will provide a forum for the discussion of the following concepts:
- What to consider when designing, conducting, and analyzing dedicated renal impairment studies
- How to estimate renal function
- How to label a drug to provide clinically relevant information on the effects of reduced renal function on the drug’s PK/PD properties
- How to integrate and interpret data from a specific drug development program to assess the effects of renal impairment on drug safety and efficacy
- How to determine the magnitude of dose adjustment required as renal function declines
- How to move from clinical trial data to real world practice when dosing special populations (i.e., morbidly obese) Register for Optimizing Dosing for the Safe and Effective Use of Drugs in Patients with Renal Impairment.
ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.
